Pharmacological treatments of cerebellar ataxia

Cerebellum

Volumn 3, Issue 2, 2004, Pages 107-111

  Ogawa, Masafumi ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Cerebellar ataxia; D cycloserine; Pharmacological treatment; Study design

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETAZOLAMIDE; BUSPIRONE; CHOLINE; CHOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; COTRIMOXAZOLE; CYCLOSERINE; DIZOCILPINE; FLUOXETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; ONDANSETRON; PHENCYCLIDINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PLACEBO; PROTIRELIN; SEROTONIN 1A AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROBIOPTERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CEREBELLAR ATAXIA; CEREBELLUM ATROPHY; CEREBELLUM DEGENERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; ELECTROMYOGRAPHY; FRIEDREICH ATAXIA; HUMAN; MACHADO JOSEPH DISEASE; MOUSE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; REVIEW; RIGIDITY; SEROTONINERGIC SYSTEM; SIDE EFFECT; SPASTICITY; SPINOCEREBELLAR DEGENERATION; SYSTEMATIC REVIEW;

CEREBELLAR ATAXIA; CHOLINE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; CYCLOSERINE; ERGOLOID MESYLATES; HUMANS; PHYSOSTIGMINE; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN AGENTS; THYROTROPIN-RELEASING HORMONE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 2942731275     PISSN: 14734222     EISSN: None     Source Type: Journal    
DOI: 10.1080/147342204100032331     Document Type: Review

References (47)

1. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997; 145(2): 205-211.
2. Ogawa M, Shigeto H, Yamamoto T, Oya Y, Wada K, Nishikawa T, et al. D-cycloserine for the treatment of ataxia in spinocerebellar degeneration. J Neurol Sci 2003; 210(1-2): 53-56.
3. Hardman JG, Limbird LE, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 9th edn. New York,: McGraw-Hill, 1996.
4. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neuroscience Letters 1989; 98(1): 91-95.
5. Kark RA, Blass JP, Spence MA. Physostigmine in familial ataxias. Neurology 1977; 27(1): 70-72.
6. Kark RA, Budelli MM, Wachsner R. Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias. Neurology 1981; 31(3): 288-292.
7. Rodriguez-Budelli MM, Kark RA, Blass JP, Spence MA. Action of physostigmine on inherited ataxias. Adv Neurol 1978; 21: 195-202.
8. Kish SJ, Schut L, Simmons J, Gilbert J, Chang LJ, Rebbetoy M. Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy. J Neurol Neurosurg Psychiatry 1988; 51(4): 544-548.
9. Kanazawa I, Kwak S, Sasaki H, Mizusawa H, Muramoto O, Yoshizawa K, et al. Studies on neurotransmitter markers and neuronal cell density in the cerebellar system in olivopontocerebellar atrophy and cortical cerebellar atrophy. J Neurol Sci 1985; 71(2-3): 193-208.
10. Wessel K, Langenberger K, Nitschke MF, Kompf D. Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases. Arch Neurol 1997; 54(4): 397-400.
11. Barbeau A. Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can J Neurol Sci 1978; 5(1): 157-160.
12. Reding MJ, Blass JP, Stern PH, Diponte P. Lecithin in hereditary ataxia. Neurology 1981; 31(3): 363-364.
13. Filla A, Campanella G. A six-month phosphatidylcholine trial in Friedreich's ataxia. Can J Neurol Sci 1982; 9(2): 147-150.
14. Finocchiaro G, Di Donato S, Madonna M, Fusi R, Ladinsky H, Consolo S. An approach using lecithin treatment for olivopontocerebellar atrophies. Eur Neurol 1985; 24(6): 414-421.
15. Sorbi S, Piacentini S, Marini P, De Scisciolo G, Amantini A, Amaducci L. Lack of efficacy of phosphatidylcholine in ataxias. Neurology 1988; 38(4): 649-650.
16. Livingstone IR, Mastaglia FL, Pennington RJ, Skilbeck C. Choline chloride in the treatment of cerebellar and spinocerebellar ataxia. J Neurol Sci 1981; 50(2): 161-174.
17. Lawrence CM, Millac P, Stout GS, Ward JW. The use of choline chloride in ataxic disorders. J Neurol Neurosurg Psychiatry 1980; 43(5): 452-454.
18. Sehested P, Lund HI, Kristensen O. Oral choline in cerebellar ataxia. Acta Neurol Scand 1980; 62(2): 124-126.
19. Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol 1988; 45(11): 1217-1222.
20. Wessel K, Hermsdorfer J, Deger K, Herzog T, Huss GP, Kompf D, et al. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch Neurol 1995; 52(5): 451-455.
21. Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, et al. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol 1995; 52(5): 456-460.
22. Manto M, Hildebrand J, Godaux E, Roland H, Blum S, Jacquy J. Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia. Arch Neurol 1997; 54(10): 1192-1194.
23. Currier RD. A treatment for ataxia. Arch Neurol 1995; 52(5): 449.
24. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol 1995; 52(10): 982-988.
25. Trouillas P, Xie J, Adeleine P, Michel D, Vighetto A, Honnorat J, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol 1997; 54(6): 749-752.
26. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62(3): 282-284.
27. Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, et al. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol 2003; 250(6): 693-697.
28. Monte TL, Rieder CR, Tort AB, Rockenback I, Pereira ML, Silveira I, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003; 107(3): 207-210.
29. Sobue I, Yamamoto H, Konagaya M, Iida M, Takayanagi T. Effect of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration. Lancet 1980; 1(8165): 418-419.
30. Mano Y, Matsui K, Toyoshima E, Ando K. The pharmacological effect of thyrotropin-releasing hormone on ataxic mutant mice. Acta Neurol Scand 1986; 73(4): 352-358.
31. Sobue I, Takayanagi T, Nakanishi T, Tsubaki T, Uono M, Kinoshita M, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 1983; 61(2): 235-248.
32. Manto M, Godaux E, Hildebrand J, Jacquy J. Effects of TRH on ballistic wrist movements in cerebellar cortical atrophy: improvement of two genuine deficiencies but not of the major one. Eur J Neurol 1998; 5(2): 159-166.
33. Mello KA, Abbott BP. Effect of sulfamethoxazole and trimethoprim on neurologic dysfunction in a patient with Joseph's disease. Arch Neurol 1988; 45(2): 210-213.
34. Sakai T, Matsuishi T, Yamada S, Komori H, Iwashita H. Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm Gen Sect 1995; 102(2): 159-172.
35. Sakai T, Antoku Y, Matsuishi T, Iwashita H. Tetrahydrobiopterin double-blind, crossover trial in Machado-Joseph disease. J Neurol Sci 1996; 136(1-2): 71-72.
36. Schulte T, Mattern R, Berger K, Szymanski S, Klotz P, Kraus PH, et al. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001; 58(9): 1451-1457.
37. Griggs RC, Moxley RT, 3rd, Lafrance RA, McQuillen J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 1978; 28(12): 1259-1264.
38. Denier C, Ducros A, Vahedi K, Joutel A, Thierry P, Ritz A, et al. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology 1999; 52(9): 1816-1821.
39. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997; 15(1): 62-69.
40. Jen JC, Yue Q, Karrim J, Nelson SF, Baloh RW. Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry 1998; 65(4): 565-568.
41. Yabe I, Sasaki H, Yamashita I, Takei A, Tashiro K. Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta Neurol Scand 2001; 104(1): 44-47.
42. Plaitakis A, Nicklas WJ, Desnick RJ. Glutamate dehydrogenase deficiency in three patients with spinocerebellar ataxia: a new enzymatic defect? Trans Amer Neurolog Ass 1979; 104(54): 54-57.
43. Kish SJ, Robitaille Y, el AM, Gilbert J, Deck J, Chang LJ, et al. Brain amino acid reductions in one family with chromosome 6p-linked dominantly inherited olivopontocerebellar atrophy. Annals of Neurology 1991; 30(6): 780-784.
44. Petersen RC, Stillman RC. Phencyclidine: an overview. NIDA Res Monogr 1978(21): 1-17.
45. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 1994; 269(3): 1040-1048.
46. Saigoh K, Matsui K, Takahashi K, Nishikawa T, Wada K. The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice. Brain Res 1998; 808(1): 42-47.
47. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Research 1993; 16(2): 165-174.